Antares Therapeutics

Founded 2025 · Biotech · Private

Precision medicine therapeutics for cancer and serious diseases

Claim this profile

Follows are private to you and power your alerts

Updated · antaresrx.com

Sector
Biotech
Founded
2025
Latest Form D
$30M, May 2025
Total capital
$70M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$70M
2 Form D · last May 2025
17 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
1
28 pending · first 2024
Rank in peer group#481 of 1449

Capital timeline

2025FEDERAL ↑EQUITY ↓Cumulative $70M1st Form D$40M2nd Form D$30M
2025FEDERAL ↑EQUITY ↓Cumulative $70M1st Form D$40M2nd Form D$30M

Latest events

  • Private capital raisedForm D · SEC · 2nd filing$30M
  • Private capital raisedForm D · SEC · 1st filing$40M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#481 · top 33%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Adam FriedmanExecutive Officer, DirectorNamed in SEC Form D filings
  • Andrew FedderExecutive OfficerNamed in SEC Form D filings
  • Brian PiperExecutive Officer, DirectorNamed in SEC Form D filings
  • Jean-Francois FormelaDirectorNamed in SEC Form D filings
  • Jeffrey AlbersDirectorNamed in SEC Form D filings
  • Keith FlahertyDirectorNamed in SEC Form D filings
Show all 9 people
  • Menelas N. PangalosDirectorNamed in SEC Form D filings
  • Menelas N. PangalosDirectorNamed in SEC Form D filings
  • Shelley ChuDirectorNamed in SEC Form D filings

What it has protected

USPTO · 1 granted of 29
  • PendingMulticyclic CompoundsUSPTOApplication 18846616
  • GrantedMulticyclic CompoundsUSPTOUS 12,054,479
  • PendingHeterocyclic Inhibitors Of Egfr And/or HER2, For Use In The Treatment Of CancerUSPTOApplication 18030211
Show all 29 patent records
  • Multicyclic CompoundsJul 3, 2025 · Application 18846616Pending
  • Multicyclic CompoundsAug 6, 2024 · US 12,054,479Granted
  • Heterocyclic Inhibitors Of Egfr And/or HER2, For Use In The Treatment Of CancerMar 28, 2024 · Application 18030211Pending
  • PYRROLO[3,2-C]PYRIDIN-4-ONE Derivatives Useful In The Treatment Of CancerNov 16, 2023 · Application 18027316Pending
  • Therapeutic AgentsApplication 63804335Pending
  • Therapeutic AgentsApplication 63721100Pending
  • Methods For Treating CancerApplication PCTUS2024051886Pending
  • Methods For Treating CancerApplication PCTUS2024051934Pending
  • Methods Of Treating CancerApplication PCTUS2024049606Pending
  • Methods Of Treating CancerApplication PCTUS2024044669Pending
  • Methods For Treating CancerApplication 63667463Pending
  • Methods For Treating CancerApplication PCTUS2024032793Pending
  • Methods For Treating CancerApplication PCTUS2024032749Pending
  • Methods For Treating CancerApplication PCTUS2023077433Pending
  • Methods For Treating CancerApplication PCTUS2023077441Pending
  • Methods For Treating A P53-ASSOCIATED CancerApplication 19579776Pending
  • Methods For Treating CancerApplication 19121282Pending
  • Egfr Inhibitor For Use In The Treatment Of Lung Cancer Positive For An Egfr Exon 20 MutationApplication 19514963Pending
  • Methods For Treating P53-ASSOCIATED CancerApplication 19579768Pending
  • Methods Of Treating Cancer Using Egfr InhibitorsApplication 19525386Pending
  • Indolizine Derivatives For Treating CancerApplication 19120060Pending
  • Methods For Treating CancerApplication PCTUS2026011996Pending
  • Methods For Treating CancerApplication 63837450Pending
  • Methods For Treating CancerApplication 63774528Pending
  • A 1,5-DIHYDRO-4H-PYRROLO[3,2-C] PYRIDIN-4-ONE For Use In The Treatment Of CancerApplication 19490934Pending
  • Methods For Treating CancerApplication 63748262Pending
  • A 1,5-DIHYDRO-4H-PYRROLO[3,2-C] PYRIDIN-4-ONE For Use In The Treatment Of CancerApplication 19490935Pending
  • Therapeutic AgentsApplication PCTUS2025055569Pending
  • Methods For Treating CancerApplication PCTUS2025036219Pending
  • Accent TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • Affinia TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • PRECISION BIOSCIENCES INCSimilar federal contract value in Biotech · null in contracts
  • Caldera TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • Ethyreal BioSimilar federal contract value in Biotech · null in contracts
  • Dyne TherapeuticsSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .